Cancer, 2018-11, Vol.124 (22), p.4276-4278
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Neoadjuvant therapy for esophageal cancer: Who, when, and what?
- Ist Teil von
- Cancer, 2018-11, Vol.124 (22), p.4276-4278
- Ort / Verlag
- United States: Wiley Subscription Services, Inc
- Erscheinungsjahr
- 2018
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- The perioperative combination of 5‐fluorouracil, oxaliplatin, and docetaxel is a new standard treatment in patients with esophageal carcinoma. However, chemoradiation results in higher R0 surgical resection rates, pathologic complete response, and negative lymph node status. The identification of molecular subsets may influence the design of future studies and guide drug development.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0008-543XeISSN: 1097-0142DOI: 10.1002/cncr.31768Titel-ID: cdi_proquest_miscellaneous_2141046865
- Format
- –
- Schlagworte
- 5-Fluorouracil, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Chemoradiotherapy, Chemoradiotherapy, Adjuvant - methods, Clinical Trials as Topic, Drug development, Esophageal cancer, Esophageal carcinoma, Esophageal Neoplasms - therapy, Esophagus, Female, Humans, Lymph nodes, Male, Neoadjuvant Therapy - methods, Oncology, Oxaliplatin, Preoperative Care, Randomized Controlled Trials as Topic, Surgery, Therapeutic Equipoise, Treatment Outcome